IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)PRNewsWire • 05/08/26
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens BermanGlobeNewsWire • 05/08/26
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitPRNewsWire • 05/08/26
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLPGlobeNewsWire • 05/07/26
IMMUNITYBIO, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs ImmunityBio, Inc. (IBRX) Investors of a Securities Fraud LawsuitNewsfile Corp • 05/07/26
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming DeadlineGlobeNewsWire • 05/07/26
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 MillionBusiness Wire • 05/07/26
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their RightsGlobeNewsWire • 05/06/26
SHAREHOLDER ALERT Securities Class Action Filed Against ImmunityBio, Inc. (IBRX)Newsfile Corp • 05/06/26
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & KorsinskyPRNewsWire • 05/06/26
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 05/05/26
IBRX Deadline Alert: The Gross Law Firm Reminds ImmunityBio, Inc. (IBRX) Investors of Securities Class Action Deadline on May 26, 2026PRNewsWire • 05/05/26
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual MeetingBusiness Wire • 05/05/26
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & KorsinskyGlobeNewsWire • 05/05/26
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewsWire • 05/04/26
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 05/01/26
IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, Inc. Securities Lawsuit - Contact The Gross Law FirmGlobeNewsWire • 05/01/26
INVESTOR REMINDER: Berger Montague Notifies ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Class Action Lawsuit and DeadlinePRNewsWire • 04/30/26
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallStPRNewsWire • 04/30/26
Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.Business Wire • 04/29/26
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Promoted Unapproved Drug Uses: Levi & KorsinskyPRNewsWire • 04/29/26
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens BermanGlobeNewsWire • 04/28/26